ReviewBone marrow transplantation2005
T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up!
Review in Bone marrow transplantation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.Cancer immunology, immunotherapy : CII · 2012Trial
- T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2007Trial
- Stem cell and gene therapies for leukodystrophies.Molecular therapy. Methods & clinical development · 2025Review
- Detecting T-cell clonal expansions and quantifying clone survival using deep profiling of immune repertoires.Frontiers in immunology · 2024Article
- Anti-thymocyte globulin-mediated immunosenescent alterations of T cells in kidney transplant patients.Clinical & translational immunology · 2022Article
- Interleukin-21 promotes thymopoiesis recovery following hematopoietic stem cell transplantation.Journal of hematology & oncology · 2017Article
- Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.Cytokine · 2015Article
- Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013Article
- Article
- Promoting transplantation tolerance; adoptive regulatory T cell therapy.Clinical and experimental immunology · 2013Review
- Recombinant IL-7/HGFβ efficiently induces transplantable murine hematopoietic stem cells.The Journal of clinical investigation · 2012Article
- The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases.Intractable & rare diseases research · 2012Review
- Hematopoietic progenitor migration to the adult thymus.Annals of the New York Academy of Sciences · 2011Review
- Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.Journal of neuro-oncology · 2010Article
- Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.PloS one · 2010Article
- Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.Journal of immunology (Baltimore, Md. : 1950) · 2006Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adoptive immunotherapy is the isolation and infusion of antigen-specific or nonspecific lymphocytes. Adoptive therapy with T cells may have a role in replacing, repairing, or enhancing immune function damaged by cytotoxic therapies, and rapid lymphocyte recovery may improve outcome after autologous and allogeneic stem cell transplantation (SCT). Recently, a plethora of information on the basic mechanisms of T-cell biology and regulation of cellular immune responses has emerged, permitting the development of new forms of adoptive cell therapy. Efficient ex vivo culture method for T-cell subsets affords the possibility of adoptive transfer of T cells engineered with enhanced capacity for central memory, effector cytotoxicity, Th1, Th2, veto cell, and T regulatory functions. Studies show that homeostatic T-cell proliferation is important for effective adoptive immunotherapy and pretreatment with chemotherapy may enhance the effects of infused T cells. Replicative senescence, in part due to telomere erosion, likely limits successful adoptive immunotherapy, though it may be possible to maintain T-cell pools by enforced expression of telomerase. Clinical trials now demonstrate that it is possible to enhance immune reconstitution after SCT with cytokines or infusions of ex vivo costimulated expanded T cells. These data all support the premise that adoptive therapy can accelerate reconstitution of cellular immunity with enhanced antitumor effects following SCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.